Haixiang Wu

Title: Haixiang Wu - Innovator in Bispecific Recombinant Proteins

Introduction

Haixiang Wu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of bispecific recombinant proteins. His innovative work aims to enhance cancer treatment through targeted therapies.

Latest Patents

Haixiang Wu holds a patent for a bispecific recombinant protein, which includes a high affinity tumor-targeting arm and a low affinity fusion protein that blocks the interaction of CD47 with SIRPα. This groundbreaking invention is designed to improve the binding affinity to target antigens on tumor cells, making it at least six times more effective than traditional monomer fusion protein homodimers. The patent also encompasses nucleic acid molecules that encode these recombinant proteins, which can be utilized in the manufacture of medicaments for treating tumors.

Career Highlights

Wu is associated with Shanghai JMT-Bio Technology Co., Ltd., where he continues to push the boundaries of biopharmaceutical research. His work is pivotal in the ongoing quest for more effective cancer therapies, showcasing his commitment to advancing medical science.

Collaborations

He collaborates with notable colleagues, including Liping Song and Xiaotian Cui, who contribute to his research endeavors and help in the development of innovative solutions in biotechnology.

Conclusion

Haixiang Wu's contributions to the field of bispecific recombinant proteins represent a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire progress in the biopharmaceutical industry.